Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity

 Your competent? doctor already has EXACT PROTOCOLS for these already, right! Oh no, nothing exists because your doctor and hospital ARE COMPLETELY FUCKING INCOMPETENT!

In my opinion I expect my doctor, therapists and hospital to be completely up-to-date on all research that gets survivors recovered! That is competence defined properly!

• psilocybin (50 posts to May 2014)

• psilocin (2 posts to May 2024)

• DMT (8 posts to November 2020)

• LSD (5 posts to September 2018)

• magic mushrooms (10 posts to October 2014) 

Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity

Abstract INTRODUCTION: Serotonergic psychedelics such as LSD, psilocin, and DMT have shown significant potential for the treatment of neuropsychiatric disorders including depression, addiction, and anxiety accompanying life-threatening illnesses. Although the effects of these substances on neuronal activity and neuroplasticity have been demonstrated, a deeper understanding of their mechanisms of action is essential for the development of new treatments. 

OBJECTIVES: The main objective of this study was to determine the effects of the serotonergic psychedelics LSD, psilocin, and DMT on neurotransmitter release and their influence on the activity of neuronal networks. The study also addressed possible mechanisms involved in this modulation. METHODS: To monitor the effects of psychedelics on key presynaptic mechanisms, we used genetically encoded sensors that allow for the monitoring of synaptic vesicle fusion, synaptopHluorin, glutamate release, iGluSnFR, and presynaptic calcium levels, synGCaMP6, expressed in primary rat cortical cultures. A pharmacological approach using agonists and antagonists of these receptors was used to study the effects of individual types of 5-HT receptors. Immunofluorescence staining and western blotting were used to assess the levels and phosphorylation states of several key regulators of presynaptic functions and neuroplasticity. To assess the acute effects...

Citace dokumentu

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons

But hasn't your doctor already prescribed psilocybin for your stroke recovery? WHY NOT? They are that fucking incompetent?

• psilocybin (26 posts to May 2014)

 Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons

Psilocin fosters neuroplasticity in iPSC-derived
human cortical neurons
Philipp Koch
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
https://orcid.org/0000-0003-3713-8786
Malin Schmidt
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
Anne Hoffrichter
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
https://orcid.org/0000-0001-6009-7826
Mahnaz Davoudi
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
Sandra Horschitz
Central Institute of Mental Health
Thorsten Lau
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
Marcus Meinhardt
Central Institute for Mental Health https://orcid.org/0000-0002-5103-0731
Rainer Spanagel
Central Institute of Mental Health
Julia Ladewig
Central Institute of Mental Health (ZI), Medical Faculty Mannheim, Heidelberg University
https://orcid.org/0000-0002-5943-7990
Georg Köhr
Central Institute of Mental Health
Article
Keywords:
Posted Date: June 7th, 2024
DOI: https://doi.org/10.21203/rs.3.rs-4242829/v1

Abstract

Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from induced pluripotent stem cells with the 5-HT2A receptor agonist psilocin - the psychoactive metabolite of psilocybin. We analyzed how exposure to psilocin affects 5-HT2A receptor localization, gene expression, neuronal morphology, synaptic markers and neuronal function. Upon exposure of human neurons to psilocin, we observed a decrease of cell surface-located 5-HT2A receptors first in the axonal- followed by the somatodendritic-compartment. Psilocin further provoked a 5-HT2A-R-mediated augmentation of BDNF abundance. Transcriptomic profiling identified gene expression signatures priming neurons to neuroplasticity. On a morphological level, psilocin induced enhanced neuronal complexity and increased expression of synaptic proteins, in particular in the postsynaptic-compartment. Consistently, we observed an increased excitability and enhanced synaptic network activity in neurons treated with psilocin. In conclusion, exposure of human neurons to psilocin might induces a state of enhanced neuronal plasticity which could explain why psilocin is beneficial in the treatment of neuropsychiatric disorders where synaptic dysfunctions are discussed.

Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders

 You'll have to ask your competent? doctor the difference between psilocybin and psilocin because your doctor should already be familiar with all the benefits of psilocybin for stroke.

magic mushrooms (10 posts to October 2014)

psilocybin (14 posts to May 2014)

The latest here:

Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

“At Enveric, our drug-discovery engine has created more promising, patented therapeutics than we can commercialize alone, so finding a partner such as MindBio Therapeutics, that shares our passion to develop much-needed treatments for neuropsychiatric indications like depression, is a big win,” Joseph Tucker, PhD, Enveric Biosciences CEO, told Healio in an email.

Enveric Biosciences has signed a nonbinding term sheet with MindBio Therapeutics, which will seek to advance a novel psilocin prodrug candidate for neuropsychiatric indications. Image: Adobe Stock

According to an Enveric press release, the company’s psilocin prodrug molecules are designed to release therapeutic levels of systemic psilocin at varying rates for treatment of anxiety, depression and substance abuse disorders. Other features include enhanced gastrointestinal stability, increased absorption properties and variable cleavable substitutions producing altered pharmacokinetic properties.

Terms of the signing permit MindBio to advance a drug candidate from Enveric’s novel psilocin prodrug class for neuropsychiatric indications. Upon entering into a definitive agreement, MindBio would receive an exclusive, global license to the formulations, drugs, method of use and devices developed to utilize the compound. MindBio would also assume responsibility for all future preclinical, clinical and commercial development on a royalty-bearing basis for all human and animal pharmaceutical applications, the also additionally revealed in the release.

Should a definitive agreement be reached, MindBio would pay Enveric development and sales milestones up to an aggregate $66.5 million as well as royalties ranging from 2.5% to 10% on all future sales.

“Enveric’s efforts are directed to maximize benefit to the patient and return to the shareholder by advancing as many of our drug candidates as possible, and these efforts are significantly facilitated when we find opportunities to do so in concert with equally committed partners,” Tucker told Healio.